Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis

Core Insights - NXC-201, a CAR-T cell therapy, shows significant clinical activity in treating relapsed/refractory AL Amyloidosis, achieving a 75% complete response rate in a small patient cohort [1][2][5] - The therapy has a favorable safety profile, particularly in frail patients, and is currently being evaluated in ongoing clinical trials in the U.S. [1][6] Company Overview - Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and select immune-mediated diseases [10] - The company’s lead candidate, NXC-201, has received Orphan Drug Designation from the FDA and EMA for AL Amyloidosis [6][10] Clinical Trials - NEXICART-1 is an open-label, ex-U.S. Phase 1b/2 clinical trial that has reported promising results for NXC-201 in patients with relapsed/refractory AL Amyloidosis [3][5] - NEXICART-2 is a U.S. Phase 1b/2 trial designed to evaluate NXC-201 in patients with preserved heart function, aiming to enroll 40 patients [4][6] Market Potential - The prevalence of relapsed/refractory AL Amyloidosis in the U.S. is projected to grow at 12% annually, reaching approximately 33,277 patients by 2024 [8] - The amyloidosis market was valued at $3.6 billion in 2017 and is expected to grow to$6 billion by 2025 [9]